Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Daniel O. Nwankwo"'
Autor:
Salimat O. Sofela, Damilola S. Bodun, Damilola A. Omoboyowa, Precious A. Ajiboro, Daniel O. Nwankwo, Zainab Ashimiyu-Abdusalam, Ibidun B. Issac, Buhari Abdulrasheed, Toheeb A. Balogun, Ifetayo H. Ajayi
Publikováno v:
Informatics in Medicine Unlocked, Vol 42, Iss , Pp 101368- (2023)
Gefitinib, an established anticancer medication targeting Epidermal Growth Factor Receptor (EGFR), has faced challenges due to tumor resistance and relapse over time. A notable factor in Gefitinib resistance is the elevated expression of FGFR2. Combi
Externí odkaz:
https://doaj.org/article/32b92400f4a64a8fbb4629f0fe3f21fc
Autor:
Precious A. Akinnusi, Samuel O. Olubode, Ayomide O. Adebesin, Temidayo J. Osadipe, Daniel O. Nwankwo, Aanuoluwapo D. Adebisi, Bisi-Adeniyi Titilayo I, Yetunde M. Alo, Afolabi Owoloye, Kolapo M. Oyebola
Publikováno v:
Informatics in Medicine Unlocked, Vol 38, Iss , Pp 101206- (2023)
Resistance of malaria parasites to antimalarial drugs is a huge public health concern. Partial resistance of Plasmodium falciparum to artemisinin has been reported in many malaria-endemic regions. Therefore, there is a need to develop new and potent
Externí odkaz:
https://doaj.org/article/ff996a32fa2544ce8acba341c6630820
Autor:
Samuel O Olubode, Mutolib O Bankole, Precious A Akinnusi, Olayinka S Adanlawo, Kehinde I Ojubola, Daniel O Nwankwo, Onome E Edjebah, Ayomide O Adebesin, Abigail O Ayodele
Publikováno v:
Cancer Informatics, Vol 21 (2022)
Prostate cancer is the second most common disease in men and the sixth leading cause of death from cancer globally, with 20 million men expected to be affected by 2024 thus considered as chronic illness which requires immediate attention. As an andro
Externí odkaz:
https://doaj.org/article/0f10cb7f391c49379aff59bc5482f107